MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Kodu・Aktsiate loetelu・Denali Therapeutics Inc

Denali Therapeutics Inc

Suletud

SektorTervishoid

20.56 4.74

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

19.67

Max

20.62

Põhinäitajad
By Trading Economics
Sissetulek	-1.6M -129M
Töötajad	503
EBITDA	8.9M -125M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+78.25% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-390M 2.9B
Eelmine avamishind	15.82
Eelmine sulgemishind	20.56

Uudiste sentiment

By Acuity

26%

74%

95 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

13.355 / 16.44 Toetus ja vastupanu

Denali Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. apr 2026, 17:11 UTC

Suurimad hinnamuutused turgudel

Uudisväärsed sündmused

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2. apr 2026, 17:10 UTC

Uudisväärsed sündmused

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

3. apr 2026, 00:00 UTC

Uudisväärsed sündmused

How Insulated Is the U.S. Economy From the Iran War? -- WSJ

2. apr 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2. apr 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2. apr 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2. apr 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2. apr 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2. apr 2026, 21:01 UTC

Uudisväärsed sündmused

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2. apr 2026, 20:59 UTC

Omandamised, ülevõtmised, äriostud

Starbucks and Boyu Capital Finalize China JV

2. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

2. apr 2026, 20:41 UTC

Tulu

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2. apr 2026, 20:32 UTC

Market Talk

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2. apr 2026, 20:30 UTC

Omandamised, ülevõtmised, äriostud

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2. apr 2026, 20:09 UTC

Market Talk

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2. apr 2026, 20:01 UTC

Omandamised, ülevõtmised, äriostud

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2. apr 2026, 19:46 UTC

Market Talk

Is Oil the New GameStop? -- Market Talk

2. apr 2026, 19:35 UTC

Market Talk

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2. apr 2026, 19:29 UTC

Omandamised, ülevõtmised, äriostud

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2. apr 2026, 19:24 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2. apr 2026, 19:20 UTC

Market Talk

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2. apr 2026, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2. apr 2026, 19:00 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific: Agreement Reached With American Train Dispatchers Association

2. apr 2026, 18:24 UTC

Omandamised, ülevõtmised, äriostud

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2. apr 2026, 17:44 UTC

Market Talk

Uudisväärsed sündmused

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2. apr 2026, 17:32 UTC

Uudisväärsed sündmused

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2. apr 2026, 17:26 UTC

Tulu

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2. apr 2026, 17:17 UTC

Market Talk

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2. apr 2026, 17:09 UTC

Market Talk

Uudisväärsed sündmused

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Denali Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

78.25% tõus

12 kuu keskmine prognoos

Keskmine 35.08 USD 78.25%

Kõrge 42 USD

Madal 25 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Denali Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

Osta

Hoia

Müü

Põhineb 15 analüütiku instrumendi Denali Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

13.355 / 16.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

95 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.